Pharyngitis secondary prevention

Jump to navigation Jump to search

Pharyngitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pharyngitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pharyngitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pharyngitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pharyngitis secondary prevention

CDC on Pharyngitis secondary prevention

Pharyngitis secondary prevention in the news

Blogs on Pharyngitis secondary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Pharyngitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [2]

Overview

Secondary prevention of pharyngitis is crucial in patients have developed acute rheumatic fever (ARF), rheumatic heart disease (RHD) or post streptococcal glomerulonephritis, as they are at high risk for recurrent ARF and progressive RHD with subsequent episodes of GAS pharyngitis. Therefore, strategies for secondary prevention of disease recurrence are necessary to reduce morbidity and mortality in patients with a history of ARF and/or RHD.

Secondary Prevention

Strategies for secondary prevention of disease recurrence are necessary to reduce morbidity and mortality in patients with a history of ARF and/or RHD. At the time of diagnosis of ARF, a course of therapy for treatment of GAS pharyngitis should be initiated. Once it is completed, a prophylaxis regimen should be initiated which include intramuscular benzathine penicillin G every 3–4 weeks or twice-daily oral penicillin is preferred, and sulfadiazine or macrolides are acceptable in the penicillin-allergic patient.

Prophylaxis is continued into adulthood, with the duration of prophylaxis depending on the severity of carditis, if present.[1]

Severity of Rheumatic fever with carditis Prophylactic management
Patients with ARF but withour carditis Prophylaxis for at least 5 years or until 21 years of age (whichever is longer)
Patients with ARF associate with carditis but without any residual valvular disease Prophylaxis for at least 10 years or until 21 years of age (whichever is longer)
Patients with ARF associate with carditis and residual valvular disease Prophylaxis for at least until 40 years of age

Routine treatment of asymptomatic GAS carriers is not indicated, unless during a recurrent GAS outbreak among family members, outbreak of rheumatic fever , or in a patient with a personal history of acute rheumatic fever or rheumatic heart disease. Chemoprophylaxis with penicillin (or macrolides if there is penicillin allergy) should be considered for GAS carriers with a well-documented history of rheumatic fever or rheumatic heart disease. Tonsillectomy may be an option for patients with recurrent streptococcal infections. Safe sex counseling to avoid HIV, Neisseria gonorrhoeae or Chlamydia transmission.[2]

Secondary Prevention

Reference

Template:WH Template:WS